American Journal of Psychiatry
Fecha de publicación: 14 de mayo de 2021
Autores: Yash B. Joshi, M.D., Ph.D., Michael L. Thomas, Ph.D., David L. Braff, M.D., Michael F. Green, Ph.D., Ruben C. Gur, Ph.D., Raquel E. Gur, M.D., Ph.D., Keith H. Nuechterlein, Ph.D., William S. Stone, Ph.D., Tiffany A. Greenwood, Ph.D., Laura C. Lazzeroni, Ph.D., Laura R. MacDonald, B.S., Juan L. Molina, M.D., John A. Nungaray, B.S., Allen D. Radant, M.D., Jeremy M. Silverman, Ph.D., Joyce Sprock, B.A., Catherine A. Sugar, Ph.D., Debby W. Tsuang, M.D., Ph.D., Ming T. Tsuang, M.D., Ph.D., Bruce I. Turetsky, M.D., Neal R. Swerdlow, M.D., Ph.D., Gregory A. Light, Ph.D
DOI: https://doi.org/10.1176/appi.ajp.2020.20081212
Background: Many psychotropic medications used to treat schizophrenia have significant anticholinergic properties, which are linked to cognitive impairment and dementia risk in healthy subjects. Clarifying the impact of cognitive impairment attributable to anticholinergic medication burden may help optimize cognitive outcomes in schizophrenia. The aim of this study was to comprehensively characterize how this burden affects functioning across multiple cognitive domains in schizophrenia outpatients.
